Carisma Therapeutics, Inc.
CARM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.02 | -0.16 | -9.99 |
| FCF Yield | -345.82% | -83.80% | -2.49% | -26.38% |
| EV / EBITDA | -0.03 | -0.28 | -9.02 | 1.65 |
| Quality | ||||
| ROIC | -385.25% | -117.40% | -98.39% | -0.37% |
| Gross Margin | -203.96% | -396.85% | 100.00% | 99.68% |
| Cash Conversion Ratio | 0.99 | 0.93 | 0.12 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 25.92% | -17.47% | -4.35% | – |
| Free Cash Flow Growth | 27.06% | -573.23% | 68.81% | -42.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.27 | 0.87 | -0.28 | 19.08 |
| Interest Coverage | 0.00 | 0.00 | -17.86 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 40.52 | -19.37 | 0.00 | -11,914.32 |